Dynavax Technologies Revenue 2010-2023 | DVAX

Dynavax Technologies revenue from 2010 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Dynavax Technologies Annual Revenue
(Millions of US $)
2022 $723
2021 $439
2020 $47
2019 $35
2018 $8
2017 $0
2016 $11
2015 $4
2014 $11
2013 $11
2012 $10
2011 $22
2010 $24
2009 $40
Dynavax Technologies Quarterly Revenue
(Millions of US $)
2023-03-31 $47
2022-12-31 $184
2022-09-30 $168
2022-06-30 $256
2022-03-31 $114
2021-12-31 $195
2021-09-30 $108
2021-06-30 $53
2021-03-31 $83
2020-12-31 $20
2020-09-30 $13
2020-06-30 $3
2020-03-31 $11
2019-12-31 $11
2019-09-30 $11
2019-06-30 $8
2019-03-31 $6
2018-12-31 $5
2018-09-30 $1
2018-06-30 $1
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $7
2016-09-30 $0
2016-06-30 $3
2016-03-31 $1
2015-12-31 $1
2015-09-30 $1
2015-06-30 $2
2015-03-31 $1
2014-12-31 $2
2014-09-30 $2
2014-06-30 $3
2014-03-31 $3
2013-12-31 $3
2013-09-30 $3
2013-06-30 $3
2013-03-31 $2
2012-12-31 $2
2012-09-30 $3
2012-06-30 $3
2012-03-31 $2
2011-12-31 $11
2011-09-30 $1
2011-06-30 $7
2011-03-31 $2
2010-12-31 $2
2010-09-30 $12
2010-06-30 $2
2010-03-31 $8
2009-12-31 $2
2009-09-30 $3
2009-06-30 $16
2009-03-31 $19
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.430B $0.723B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.076B 8.19
GSK (GSK) United Kingdom $70.106B 9.78
Bio-Rad Laboratories (BIO.B) United States $11.071B 29.60
QIAGEN (QGEN) Netherlands $10.491B 22.15
Ginkgo Bioworks Holdings (DNA) United States $3.170B 0.00
Arcus Biosciences (RCUS) United States $1.611B 0.00
Biohaven (BHVN) United States $1.059B 0.00
Emergent Biosolutions (EBS) United States $0.412B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.175B 0.00
Enzo Biochem (ENZ) United States $0.114B 0.00
SQZ Biotechnologies (SQZ) United States $0.017B 0.00